top of page
  • Writer's pictureFutureMeds

Osteoporosis is a major health problem in Europe, North America, Oceania, Asia & South America

Updated: Jan 24, 2023

It is estimated that one in three women and one in five men over 50 suffer osteoporotic fractures. In fact, “an osteoporotic fracture occurs every three seconds”, according to the Global prevalence of Osteoporosis among the world older adults: a comprehensive systematic review and meta-analysis paper.

Watch the Polish TVN interview on

Among the ageing population, Osteoporosis is a silent thief of health, mobility and well-being. People tend to learn about bone density loss when it is too late. Raising awareness and talking about Osteoporosis, therefore, is extremely important.

FutureMeds’ Senior Medical Director, Professor Edward Czerwinski MD PhD, has been a prominent champion of osteoporosis prevention and treatment for over 50 years. Almost all FDA-approved osteoporosis medications have been investigated by Professor Czerwinski and his teams. He has led over 46 osteoporosis trials, organised over 24 conferences, and published over 530 publications to date.

Professor Czerwinski has recently been interviewed on TVN, a Polish television station, network, media and entertainment group and talked about the importance of prevention.

Watch the interview on

“In Poland, we have the highest death rate in people who have suffered a neck or femur fracture. It’s horrifying. 28% of women and 32% of men die within a year.” mentioned Czerwinski in the interview.

To protect the health of FutureMeds patients and progress medical research, FutureMeds Poland carried out 11,610 free-of-charge bone density scans (DEXA scan), screened 586 patients and randomised 218 of them for studies between Sept 2021 and Sept 2022.

Due to experts such as Professor Czerwinski, our experienced dedicated research teams and our drive to progress osteoporosis treatment across the globe, FutureMeds provides world-leading expertise in osteoporosis research.

About FutureMeds

FutureMeds is a fast-growing independent Dedicated Research Site Network supporting pharmaceutical companies, Sponsors and CROs and contributing to research to find effective treatments and medications for all patients who need them.

FutureMeds’ Dedicated Research Site teams strive to accelerate study timelines, streamline processes, lower costs and improve data quality to help accelerate patient access to new treatments.

Through acquisitions and a strategic focus on patient experience, FutureMeds has developed qualified patient pools across Europe that enables faster patient enrollment and strong retention and help generate more accurate results.

Follow us on LinkedIn

Follow FutureMeds on LinkedIn and join a growing group of engaged, passionate healthcare and pharmaceutical professionals who are on a mission to accelerate the drug development process and achieve regulatory approval faster so patients can safely access the very latest treatments as soon as possible.


Komentowanie zostało wyłączone.
bottom of page